Plain-English translation of NCT07084480 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Giant Cell Arteritis research guide →This study invites people already diagnosed with giant cell arteritis (a condition causing inflammation of large blood vessels) or related muscle inflammation to participate in careful, long-term monitoring. Researchers will use advanced imaging scans, blood tests, and eye exams to better understand who is at risk for serious complications like aortic aneurysms, and to learn which patients respond best to which treatments. The goal is to move toward personalized medicine—tailoring therapy to each person's individual disease pattern.
Giant cell arteritis is a serious condition that can vary greatly from person to person, making it hard to predict who will develop life-threatening complications or how much steroid medication each patient really needs. This study aims to identify imaging and blood markers that could help doctors predict these risks earlier and reduce unnecessary medication side effects over the long term.
You likely qualify if…
You likely don't qualify if…
If you join, you will have regular visits at the Würzburg University Hospital's rheumatology department over 5-10 years. During these visits, you'll receive imaging scans (including MRI and special eye imaging), standard blood tests, and clinical examinations—the same care you may already be receiving, but with detailed research tracking. The study compares two groups: people already under care at the hospital, and newly diagnosed patients, to see if imaging and blood patterns can help predict complications and guide personalized treatment adjustments.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
Germany
Sponsor
Wuerzburg University Hospital
Enrollment target
~400 participants
Started
November 2025
Primary completion
July 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Michael Gernert
Wuerzburg University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.